01986nam a2200433 i 4500001001300000003000600013005001700019007001400036008004100050040003000091042000800121043001200129074001600141086002300157088008600180110006800266245019000334264006000524300002800584336000800612337001600620338001900636490002300655500003600678500002700714500002500741504004100766533010600807776015000913776015101063810006001214050002001274610005301294650003301347650004301380650004501423650005101468655003301519on1090541314OCoLC20190423081337.0he bmb024bbca190325s2018    dcu     bb   f000 0 eng c  aPUCPRbengerdacGPOdMvI  apcc  an-us---  a1042-B (MF)0 aY 4.F 49/20:115-76  aSerial no. J-113-58 (United States. Congress. Senate. Committee on the Judiciary)1 aUnited States.bCongress.bSenate.bCommittee on the Judiciary,10aOversight of the Drug Enforcement Administration :bhearing before the Committee on the Judiciary, United States Senate, One Hundred Thirteenth Congress, second session, April 30, 2014. 1aWashington :bU.S. Government Publishing Office,c2018.  aiii, 63 pages ;c24 cm.  btxt  bh2rdamedia  bhe2rdacarrier1 aS. hrg. ;v113-886  aShipping list no.: 2019-0064-M.  a"Serial no. J-113-58."  aCRDP Program record.  aIncludes bibliographical references.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2018]e1 microfiche : negative.08iPrint version:aUnited States. Congress. Senate. Committee on the Judiciary.tOversight of the Drug Enforcement Administrationw(OCoLC)106115028708iOnline version:aUnited States. Congress. Senate. Committee on the Judiciary.tOversight of the Drug Enforcement Administrationw(OCoLC)10615041881 aUnited States.bCongress.bSenate.tS. hrg. ;v113-886. 4aKF26b.J8 2014n10aUnited States.bDrug Enforcement Administration. 0aDrug controlzUnited States. 0aDrug abusezUnited StatesxPrevention. 0aOpioid abusezUnited StatesxPrevention. 0aDrugsxPrescribingzUnited StatesxManagement. 7aLegislative hearings.2lcgft